[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"robotic-bronchoscopy-system\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:robotic-bronchoscopy-system":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100633048","one-stop-diagnosis-and-treatment-for-suspected-lung-cancer-combined-rbs-ncle-obct-and-ablation-100633048",false,"NCT07521618","One-stop Diagnosis and Treatment for Suspected Lung Cancer: Combined RBS, nClE, OBCT and Ablation","An Exploratory Clinical Trial on the Integration of Detection, Sampling and Treatment of Peripheral Lung Cancer by Robotic Bronchoscopy System","One-stop","Inclusion Criteria:\n\n* Age ≥18 years, male or female.\n* High-risk pulmonary nodule\u002Ftumor maximum diameter ≤3 cm.\n* Lesion judged suitable for bronchial navigation-guided diagnosis and treatment.\n* Ineligible for surgery or refuses surgery\u002Fradiotherapy; agrees to primary ablation therapy; provides written informed consent.\n\nExclusion Criteria:\n\n* Diffuse bilateral lung lesions unresponsive to ablation.\n* Contraindication to bronchoscopy or inability to tolerate\u002Fcooperate with bronchoscopy.\n* Severe bleeding tendency or irreversible coagulopathy (PT \\>18 s, PTA \\\u003C40%).Platelet count \\\u003C70×10⁹\u002FL; anticoagulant\u002Fantiplatelet therapy discontinued \\\u003C1 week before ablation (except prophylactic low-molecular-weight heparin).\n* Severe pulmonary impairment (maximal voluntary ventilation \\\u003C40%).\n* Other metastatic tumors with widespread metastasis; life expectancy \\\u003C3 months.\n* Poor general condition: widespread metastasis, severe infection, high fever, infectious\u002Fradiation inflammation around the lesion, obvious cachexia, severe organ dysfunction, severe anemia, uncorrectable metabolic\u002Fnutritional disorders.\n* Eastern Cooperative Oncology Group (ECOG) performance status \\>2.\n* Target lesion received radiotherapy within the past 6 months.\n* Active hepatitis B, active hepatitis C, known HIV-1\u002F2 antibody positivity, or other active infections judged by the investigator to interfere with treatment.\n* History of epilepsy, psychosis, or cognitive impairment.\n* Pregnant\u002Flactating females; males or females planning conception during the trial.\n* Other conditions deemed inappropriate by the investigator.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","Using RBS as the navigation and treatment platform, precisely navigate to the target lesion. Utilize r-EUBS and nCLE to identify the lesion, and when the confocal AI model recognizes the lesion as malignant, perform a biopsy. Subsequently, under the guidance of OBCT, carry out ablation treatment of the lesion.",[27,28,29,30],"Lung Cancer (Suspected or Confirmed)","Cryoablation","Robotic Bronchoscopy System","Confocal Laser Endomicroscopy","NOT_YET_RECRUITING","2026-04-08",{"date":34,"type":35},"2026-04-13","ACTUAL",{"date":37,"type":21},"2026-04-01",{"date":39,"type":21},"2026-12-31",{"name":41,"class":42},"Guangzhou Medical University","OTHER"]